These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 22466228)

  • 1. [IDH gene mutation in brain tumors].
    Sonoda Y; Tominaga T
    No Shinkei Geka; 2012 Apr; 40(4):297-306. PubMed ID: 22466228
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of isocitrate dehydrogenase in glioma.
    Alexander BM; Mehta MP
    Expert Rev Neurother; 2011 Oct; 11(10):1399-409. PubMed ID: 21955197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomics of human glioblastoma multiforme: a glimpse of the future.
    Komotar RJ; Syed ON; Bruce JN; Connolly ES; Dunn IF; Friedlander RM
    Neurosurgery; 2008 Dec; 63(6):15. PubMed ID: 19057310
    [No Abstract]   [Full Text] [Related]  

  • 4. [IDH mutation on glioma].
    Mukasa A
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):937-40. PubMed ID: 21751529
    [No Abstract]   [Full Text] [Related]  

  • 5. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Chamberlain MC; Sanson M
    Neurology; 2015 May; 84(19):2007. PubMed ID: 25964481
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer. Puzzling patterns of predisposition.
    Pollard PJ; Ratcliffe PJ
    Science; 2009 Apr; 324(5924):192-4. PubMed ID: 19359573
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of the IDH1 codon 132 mutation in brain tumors.
    Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
    Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH-mutant giant cell glioblastoma: A neglected tumor variant?
    Leske H; Brandal P; Rushing EJ; Niehusmann P
    Clin Neuropathol; 2017; 36(6):293-295. PubMed ID: 29035191
    [No Abstract]   [Full Text] [Related]  

  • 11. Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma.
    Kálovits F; Tompa M; Nagy Á; Kálmán B
    Ideggyogy Sz; 2018 Jul; 71(7-08):237-247. PubMed ID: 30113792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-canonical IDH Mutation Frequency in IDH1-R132H-Negative Glioblastoma Patients Older Than 54 Years.
    Pryzbylski AL; Kollmeyer TM; Praska CE; Raghunathan A; Jentoft ME; Giannini C; Vaubel RA; Halling KC; Zheng G; DiGuardo MA; Kipp BR; Jenkins RB; Ida CM
    J Neuropathol Exp Neurol; 2021 Sep; 80(8):804-806. PubMed ID: 33550363
    [No Abstract]   [Full Text] [Related]  

  • 13. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma.
    Alzial G; Renoult O; Paris F; Gratas C; Clavreul A; Pecqueur C
    Oncogene; 2022 Jan; 41(5):613-621. PubMed ID: 34764443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1 and IDH2 mutations in gliomas.
    Ducray F; Marie Y; Sanson M
    N Engl J Med; 2009 May; 360(21):2248-9; author reply 2249. PubMed ID: 19469031
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib.
    Lawson McLean A
    J Neurooncol; 2023 Aug; 164(1):267-268. PubMed ID: 37561357
    [No Abstract]   [Full Text] [Related]  

  • 16. Updates in IDH-Wildtype Glioblastoma.
    Melhem JM; Detsky J; Lim-Fat MJ; Perry JR
    Neurotherapeutics; 2022 Oct; 19(6):1705-1723. PubMed ID: 35641844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1 mutations in gliomas: when an enzyme loses its grip.
    Frezza C; Tennant DA; Gottlieb E
    Cancer Cell; 2010 Jan; 17(1):7-9. PubMed ID: 20129244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter to the Editor. Prediction model of IDH wild-type glioblastoma.
    Yu ZY; Chung MH; Wang PW; Wu YC; Liao HC; Hueng DY
    J Neurosurg; 2022 Oct; 137(4):1200. PubMed ID: 36183188
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of nonlinear dimension reduction of genome-wide DNA methylome in integrated diagnosis: A case study of glioblastoma, IDH-wildtype.
    Satomi K; Saito K; Shimoyamada H; Onizuka H; Shibayama T; Hibiya T; Hayashi A; Nagahama K; Yamagishi Y; Sasaki N; Kobayashi K; Gomyo M; Nagane M; Shibahara J
    Pathol Int; 2023 Oct; 73(10):523-526. PubMed ID: 37530489
    [No Abstract]   [Full Text] [Related]  

  • 20. Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma.
    Schittenhelm J; Mittelbronn M; Meyermann R; Melms A; Tatagiba M; Capper D
    Acta Neuropathol; 2011 Nov; 122(5):651-2. PubMed ID: 21983902
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.